AgingResearch.NewsJoin free

LuMind IDSC Foundation

Company

LuMind IDSC Foundation develops one asset, in phase 1 (ACI-24 in Down syndrome). Mostly vaccine acting on APP and proteostasis.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1

  • ACI-24

    Liposomal anti-amyloid-beta vaccine designed to elicit antibodies against amyloid-beta to prevent or clear plaques

    Phase 1, Vaccine, APP, Proteostasis, Down syndrome, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials2
  • Similar companies6

Intelligence